Related references
Note: Only part of the references are listed.Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase activator, BAY 60-2770, are not dependent on endogenous nitric oxide or reduced heme
Edward A. Pankey et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2011)
Dependence of Golgi apparatus integrity on nitric oxide in vascular cells: implications in pulmonary arterial hypertension
Jason E. Lee et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2011)
Pre-conditioning with the soluble guanylate cyclase activator Cinaciguat reduces ischaemia-reperfusion injury after cardiopulmonary bypass
Tamas Radovits et al.
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY (2011)
Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase stimulator, BAY 41-8543, are modulated by nitric oxide
Adeleke M. Badejo et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2010)
BAY 41-2272 inhibits the development of chronic hypoxic pulmonary hypertension in rats
Lise Bech Thorsen et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2010)
Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study
H. A. Ghofrani et al.
EUROPEAN RESPIRATORY JOURNAL (2010)
Emerging drugs for pulmonary hypertension
Reda E. Girgis
EXPERT OPINION ON EMERGING DRUGS (2010)
Structure of Cinaciguat (BAY 58-2667) Bound to Nostoc H-NOX Domain Reveals Insights into Heme-mimetic Activation of the Soluble Guanylyl Cyclase
Faye Martin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models
Yuliya Sharkovska et al.
JOURNAL OF HYPERTENSION (2010)
CINACIGUAT, A SOLUBLE GUANYLATE CYCLASE ACTIVATOR, UNLOADS THE HEART IN ACUTE DECOMPENSATED HEART FAILURE
Erland Erdmann et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Pulmonary hypertension with left- sided heart disease
Marco Guazzi et al.
NATURE REVIEWS CARDIOLOGY (2010)
Guanylyl cyclase activator ataciguat improves vascular function and reduces platelet activation in heart failure
Andreas Schaefer et al.
PHARMACOLOGICAL RESEARCH (2010)
Novel soluble guanylyl cyclase stimulator BAY 41-2272 attenuates ischemia-reperfusion-induced lung injury
Bakytbek Egemnazarov et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2009)
Soluble Guanylate Cyclase Agonists Inhibit Expression and Procoagulant Activity of Tissue Factor
Mikhail A. Sovershaev et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2009)
Distinct molecular requirements for activation or stabilization of soluble guanylyl cyclase upon haem oxidation-induced degradation
L. S. Hoffmann et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
Stimulation of cGMP signalling protects coronary endothelium against reperfusion-induced intercellular gap formation
Sascha A. Kasseckert et al.
CARDIOVASCULAR RESEARCH (2009)
Discovery of Riociguat (BAY 63-2521): A Potent, Oral Stimulator of Soluble Guanylate Cyclase for the Treatment of Pulmonary Hypertension
Joachim Mittendorf et al.
CHEMMEDCHEM (2009)
Pharmacological Activation of Soluble Guanylate Cyclase Protects the Heart Against Ischemic Injury
Sevil Korkmaz et al.
CIRCULATION (2009)
ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association
Vallerie V. McLaughlin et al.
CIRCULATION (2009)
Cinaciguat (BAY 58-2667) Improves Cardiopulmonary Hemodynamics in Patients With Acute Decompensated Heart Failure
Harald Lapp et al.
CIRCULATION (2009)
BAY 58-2667, a nitric oxide-independent guanylyl cyclase activator, pharmacologically post-conditions rabbit and rat hearts
Thomas Krieg et al.
EUROPEAN HEART JOURNAL (2009)
First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension
F. Grimminger et al.
EUROPEAN RESPIRATORY JOURNAL (2009)
Discovery of the nitric oxide signaling pathway and targets for drug development
Nathan S. Bryan et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2009)
Role of guanylate cyclase modulators in decompensated heart failure
Veselin Mitrovic et al.
HEART FAILURE REVIEWS (2009)
Pressure-independent effects of pharmacological stimulation of soluble guanylate cyclase on fibrosis in pressure-overloaded rat heart
Hiroyuki Masuyama et al.
HYPERTENSION RESEARCH (2009)
Pulmonary hypertension in chronic heart failure
D. Bonderman et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2009)
Diagnosis, Assessment, and Treatment of Non-Pulmonary Arterial Hypertension Pulmonary Hypertension
Marius M. Hoeper et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation
Sharon Ann Hunt et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Updated Evidence-Based Treatment Algorithm in Pulmonary Arterial Hypertension
Robyn J. Barst et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Cellular and Molecular Basis of Pulmonary Arterial Hypertension
Nicholas W. Morrell et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics
Emily J. Tsai et al.
PHARMACOLOGY & THERAPEUTICS (2009)
From arginine methylation to ADMA: A novel mechanism with therapeutic potential in chronic lung diseases
Dariusz Zakrzewicz et al.
BMC Pulmonary Medicine (2009)
Acute hemodynamic response to single oral doses of BAY 60-4552, a soluble guanylate cyclase stimulator, in patients with biventricular heart failure
Veselin Mitrovic et al.
BMC Pharmacology & Toxicology (2009)
Cardioprotective effects in aged spontaneously hypertensive rats due to chronic stimulation/activation of sGC without hypotension
Emma S Jones et al.
BMC Pharmacology & Toxicology (2009)
Probing the presence of the ligand-binding haem in cellular nitric oxide receptors
B. Roy et al.
BRITISH JOURNAL OF PHARMACOLOGY (2008)
Dose-dependent beneficial hemodynamic effects of BAY 41-2272 in a canine model of acute pulmonary thromboembolism
Stefany B. A. Cau et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2008)
Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension
R. T. Schermuly et al.
EUROPEAN RESPIRATORY JOURNAL (2008)
Role of oxidative stress and nitric oxide in atherothrombosis
Edith Lubos et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2008)
Increased adhesive properties of neutrophils in sickle cell disease may be reversed by pharmacological nitric oxide donation
Andreia A. Canalli et al.
HAEMATOLOGICA (2008)
Effects of 5′-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure:: A double-blind, placebo-controlled clinical trial
Alice Behling et al.
JOURNAL OF CARDIAC FAILURE (2008)
Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521:: An ascending-dose study in healthy male volunteers
Reiner Frey et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Sustained soluble guanylate cyclase stimulation offsets nitric-oxide synthase inhibition to restore acute cardiac modulation by sildenafil
Takahiro Nagayama et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Inhaled agonists of soluble guanylate cyclase induce selective pulmonary vasodilation
Oleg V. Evgenov et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2007)
Lessons from oncology to understand and treat pulmonary hypertension
S. Adnot et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2007)
Long-term use of sildenafil in the therapeutic management of heart failure
Marco Guazzi et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Impaired tissue responsiveness to organic nitrates and nitric oxide: A new therapeutic frontier?
Yuliy Y. Chirkov et al.
PHARMACOLOGY & THERAPEUTICS (2007)
Cyclic GMP and protein kinase-G in myocardial ischaemia-reperfusion: opportunities and obstacles for survival signaling
D. S. Burley et al.
BRITISH JOURNAL OF PHARMACOLOGY (2007)
Inhibition of TGF-β induced lung fibroblast to myofibroblast conversion by phosphodiesterase inhibiting drugs and activators of soluble guanylyl cyclase
Torsten R. Dunkern et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2007)
Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension
Gregory D. Lewis et al.
CIRCULATION (2007)
Modulation of human monocyte-derived dendritic cells maturation by a soluble guanylate cyclase activator, YC-1, in a cyclic nucleotide independent manner
I-Fang Tsai et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2007)
Peroxynitrite: biochemistry, pathophysiology and development of therapeutics
Csaba Szabo et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Phosphodiesterase regulation of nitric oxide signaling
David A. Kass et al.
CARDIOVASCULAR RESEARCH (2007)
Inhaled NO as a therapeutic agent
Kenneth D. Bloch et al.
CARDIOVASCULAR RESEARCH (2007)
Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure
Guido Boerrigter et al.
HYPERTENSION (2007)
Blood pressure-independent effect of long-term treatment with the soluble heme-independent guanylyl cyclase activator HMR1766 on progression in a model of noninflammatory chronic renal damage
Kerstin Benz et al.
KIDNEY & BLOOD PRESSURE RESEARCH (2007)
Nitric oxide and peroxynitrite in health and disease
Pal Pacher et al.
PHYSIOLOGICAL REVIEWS (2007)
Significant pharmacokinetic and pharmacodynamic interaction of warfarin with the NO-independent sGC activator HMR1766
Heike Oberwittler et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Effect of BAY 41-2272 in the pulmonary hypertension induced by heparin-protamine complex in anaesthetized dogs
Cristiane F. Freitas et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2007)
Shattuck Lecture: Nitric oxide and cyclic GMP in cell signaling and drug development
Ferid Murad
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Soluble guanylate cyclase stimulation on cardiovascular remodeling in angiotensin II-induced hypertensive rats
Hiroyuki Masuyama et al.
HYPERTENSION (2006)
Acrylamide analog as a novel nitric oxide-independent soluble guanylyl cyclase activator
Masaki Nakane et al.
JOURNAL OF PHARMACOLOGICAL SCIENCES (2006)
Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels
Johannes-Peter Stasch et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Cross talk between endothelial and smooth muscle cells in pulmonary hypertension - Critical role for serotonin-induced smooth muscle hyperplasia
S Eddahibi et al.
CIRCULATION (2006)
Biochemistry and pharmacology of novel anthranilic acid derivatives activating heme-oxidized soluble guanylyl cyclase
U Schindler et al.
MOLECULAR PHARMACOLOGY (2006)
Recent Advances in Understanding Endothelial Dysfunction in Atherosclerosis
Zhihong Yang et al.
CLINICAL MEDICINE & RESEARCH (2006)
Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling
R Dumitrascu et al.
CIRCULATION (2006)
BAY 41-2272, a direct activator of soluble guanylate cyclase, reduces right ventricular hypertrophy and prevents pulmonary vascular remodeling during chronic hypoxia in neonatal rats
Philippe Deruelle et al.
BIOLOGY OF THE NEONATE (2006)
NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential
Oleg V. Evgenov et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Pulmonary vascular effects of nitric oxide-cGMP augmentation in a model of chronic pulmonary hypertension in fetal and neonatal sheep
P Deruelle et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2005)
Explaining the phenomenon of nitrate tolerance
T Münzel et al.
CIRCULATION RESEARCH (2005)
Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells
J Wharton et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2005)
Pathophysiology of coronary artery disease
P Libby et al.
CIRCULATION (2005)
Nitrosative stress and pharmacological modulation of heart failure
P Pacher et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2005)
Mechanisms of disease - Inflammation, atherosclerosis, and coronary artery disease
GK Hansson
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension
S Pullamsetti et al.
FASEB JOURNAL (2005)
Effects of BAY 41-2272, a soluble guanylate cyclase activator, on pulmonary vascular reactivity in the ovine fetus
P Deruelle et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2005)
Efficacy and optimal dose of sildenafil in primary pulmonary hypertension
A Chockalingam et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2005)
Inhibition of phosphodiesterase type 5 by the activator of nitric oxide-sensitive guanylyl cyclase BAY 41-2272
F Mullershausen et al.
CIRCULATION (2004)
The inhibitory mechanism of YC-1, a benzyl indazole, on smooth muscle cell proliferation: an in vitro and in vivo study
CH Wu et al.
JOURNAL OF PHARMACOLOGICAL SCIENCES (2004)
Antiinflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment
A Ahluwalia et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Hemodynamic response to sildenafil, nitric oxide, and iloprost in primary pulmonary hypertension
HH Leuchte et al.
CHEST (2004)
Effects of the sGC stimulator BAY 41-2272 are not mediated by phosphodiesterase 5 inhibition
E Bischoff et al.
CIRCULATION (2004)
Impaired L-arginine transport and endothelial function in hypertensive and genetically predisposed normotensive subjects
MP Schlaich et al.
CIRCULATION (2004)
A comparative study of sildenafil, NCX-911 and BAY41-2272 on the anococcygeus muscle of diabetic rats
JS Kalsi et al.
INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH (2004)
Reduced cGMP signaling associated with neointimal proliferation and vascular dysfunction in late-stage atherosclerosis
VO Melichar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Combination of isosorbide dinitrate and hydralazine in blacks with heart failure
AL Taylor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Mechanisms of disease: Pulmonary arterial hypertension
HW Farber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs
OV Evgenov et al.
CIRCULATION (2004)
A concise synthesis of ortho-substituted aryl-acrylamides -: potent activators of soluble guanylyl cyclase
HQ Zhang et al.
TETRAHEDRON LETTERS (2003)
Antiplatelet properties of a novel, non-NO-based soluble guanylate cyclase activator, BAY 41-2272
AJ Hobbs et al.
VASCULAR PHARMACOLOGY (2003)
Potentiation of tumor necrosis factor-α expression by YG-1 in alveolar macrophages through a cyclic GMP-independent pathway
TL Hwang et al.
BIOCHEMICAL PHARMACOLOGY (2003)
Mechanisms of nitric oxide independent activation of soluble guanylyl cyclase
P Schmidt et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2003)
Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure
G Boerrigter et al.
CIRCULATION (2003)
A-350619: A novel activator of soluble guanylyl cyclase
LN Miller et al.
LIFE SCIENCES (2003)
Inhibition of deactivation of NO-sensitive guanylyl cyclase accounts for the sensitizing effect of YC-1
M Russwurm et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
NO- and haem-independent activation of soluble guanylyl cyclase:: molecular basis and cardiovascular implications of a new pharmacological principle
JP Stasch et al.
BRITISH JOURNAL OF PHARMACOLOGY (2002)
BAY 41-2272 activates two isoforms of nitric oxide-sensitive guanylyl cyclase
M Koglin et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2002)
YC-1-mediated vascular protection through inhibition of smooth muscle cell proliferation and platelet function
DA Tulis et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2002)
Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies
JP Stasch et al.
BRITISH JOURNAL OF PHARMACOLOGY (2002)
Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studies
JP Stasch et al.
BRITISH JOURNAL OF PHARMACOLOGY (2002)
Inhibition of extracellular Ca2+ entry by YC-1, an activator of soluble guanylyl cyclase, through a cyclic GMP-independent pathway in rat neutrophils
JP Wang et al.
BIOCHEMICAL PHARMACOLOGY (2001)
NO-independent stimulators of soluble guanylate cyclase
A Straub et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2001)
NO-independent regulatory site on soluble guanylate cyclase
JP Stasch et al.
NATURE (2001)
Synthesis and biological evaluation of novel pyrazoles and indazoles as activators of the nitric oxide receptor, soluble guanylate cyclase
DL Selwood et al.
JOURNAL OF MEDICINAL CHEMISTRY (2001)
YC-1, a benzyl indazole derivative, stimulates vascular cGMP and inhibits neointima formation
DA Tulis et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2000)
Human recombinant soluble guanylyl cyclase: Expression, purification, and regulation
YC Lee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Acute blood pressure effects of YC-1-induced activation of soluble guanylyl cyclase in normotensive and hypertensive rats
L Rothermund et al.
BRITISH JOURNAL OF PHARMACOLOGY (2000)
Share Paper
